Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04500821 · ClinicalTrials.gov registry record · NA
Evaluation of the LipiFlow System With a New Activator
A NA study, sponsored by Johnson & Johnson Surgical Vision.
- Completed
- Registry status
- NA
- Development phase
- 44
- Enrollment target
NCT04500821: Completed NA study, sponsored by Johnson & Johnson Surgical Vision.
NCT04500821 is a NA study that has completed, run by Johnson & Johnson Surgical Vision. The registered enrollment target is 44 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04500821, a NA study, has completed, sponsored by Johnson & Johnson Surgical Vision.
- COMPLETED
- Registry status
- NA
- Development phase
- 44 participants
- Enrollment target
Study Summary
Minimum 50 eyes and up to 100 eyes will be treated in this prospective, open-label clinical study. The investigator or designee will perform LipiFlow treatment with the Activators LFD-2100 on both eyes of a subject. The data from the treatment reports generated by the LipiFlow console and from the questionnaire will be used to assess the clinical utilization of the Activator LFD-2100. This study will be conducted in up to four sites in the USA.
Primary Outcome
Evaluation of the clinical use of the LipiFlow system with the Activator LFD-2100
Interventions
- DEVICE Activator LFD-2100
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2020-10-02 |
| Est. Completion | 2020-10-30 |
| Phase | NA |
What the finished NCT04500821 record still lists
NCT04500821 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 44 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which Activator LFD-2100 is the first listed.
NCT04500821 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04500821 about?
NCT04500821 is a clinical study titled "Evaluation of the LipiFlow System With a New Activator". Minimum 50 eyes and up to 100 eyes will be treated in this prospective, open-label clinical study. The investigator or designee will perform LipiFlow treatment with the Activators LFD-2100 on both eyes of a subject. The data from the treatment reports generated by the LipiFlow console and from the q...
What is the current status of trial NCT04500821?
This trial is currently completed. It is a NA study. The enrollment target is 44 participants. The study started on 2020-10-02. Estimated completion is 2020-10-30.
What interventions are being tested in trial NCT04500821?
The interventions under investigation include: Activator LFD-2100 (DEVICE).
Who is sponsoring clinical trial NCT04500821?
This trial is sponsored by Johnson & Johnson Surgical Vision, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04500821's enrollment target sits among peer trials
44 1423rd of 2000 higher than 566 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02323945 · 44 participants · NA
Effects of Breathing Mild Bouts of Low Oxygen on Limb Mobility After Spinal Injury
- NCT03093909 · 44 participants · Phase 1
Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
- NCT03104491 · 44 participants · Phase 1
Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
- NCT03781765 · 44 participants · Phase 4
Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI